Unicycive Q2 net loss narrows to $1.7 million on warrant gain; operating loss rises
Unicycive reported a second-quarter 2026 net loss of $1.7 million, or $(0.06) per share, versus $6.5 million, or $(0.52) per share, a year earlier, mainly because of an $8.0 million increase in the fair value of its warrant liability. Operating expenses rose to $10.1 million from $7.0 million, and the company disclosed a June 2026 FDA Complete Response Letter for its oxylanthanum carbonate NDA that cites the same third-party manufacturing deficiencies as a June 2025 letter.
Key points
- Net loss was $1.7 million ($(0.06) per share) for the quarter ended June 30, 2026, down from $6.5 million ($(0.52) per share) a year earlier.
- Change in fair value of warrant liability was a gain of $8.0 million, compared with $0.4 million in the prior-year quarter.
- Operating expenses were $10.1 million, including G&A of $7.4 million and R&D of $2.8 million.
- Cash, cash equivalents and marketable securities totaled $61.4 million as of June 30, 2026, with expected runway into 2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.